IN8bio Inc expected to post a loss of 37 cents a share - Earnings Preview
IN8bio Inc <INAB.OQ> expected to post a loss of 37 cents a share - Earnings Preview
IN8bio Inc INAB.OQ INAB.O is expected to show no change in quarterly revenue when it reports results on August 5 (estimated) for the period ending June 30 2026
LSEG's mean analyst estimate for IN8bio Inc is for a loss of 37 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for IN8bio Inc is $5.50, about 431.4% above its last closing price of $1.04
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -0.68 | -0.69 | -0.26 | Beat | 62.3 |
Dec. 31 2026 | -0.55 | -0.62 | -0.45 | Beat | 27 |
Sep. 30 2025 | -1.25 | -1.23 | -0.85 | Beat | 30.9 |
Jun. 30 2025 | -1.68 | -1.80 | -1.24 | Beat | 31.1 |
Mar. 31 2025 | -2.00 | -2.00 | -2.10 | Missed | -5 |
Dec. 31 2024 | -2.45 | -2.25 | -1.20 | Beat | 46.7 |
Sep. 30 2024 | -4.99 | -4.80 | -4.50 | Beat | 6.3 |
Jun. 30 2024 | -5.23 | -5.04 | -5.70 | Missed | -13.1 |
This summary was machine generated August 3 at 11:47 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on IN8bio
See all newsIN8bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Biopharma firm IN8bio's Q2 net loss narrows as expenses decline
IN8bio Inc expected to post a loss of 37 cents a share - Earnings Preview
Brief: IN8BIO - Enters Capital On Demand Sales Agreement With Jonestrading For ATM Offering
IN8bio Q1 net loss narrows as R&D expenses fall